Literature DB >> 25853196

Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma.

Tian Yang1, Han Zhang2, Yi-Nan Shen2, Meng-Chao Wu2, Feng Shen2, Myron Schwartz3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25853196     DOI： 10.1038/ajg.2015.33

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  5 in total

1.  Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.

Authors:  Hiroyuki Fukuda; Kazushi Numata; Satoshi Moriya; Yu Shimoyama; Tomohiro Ishii; Akito Nozaki; Masaaki Kondo; Manabu Morimoto; Shin Maeda; Kentaro Sakamaki; Satoshi Morita; Katsuaki Tanaka
Journal:  Radiology       Date:  2014-04-02       Impact factor: 11.105

Review 2.  Propensity scores and the surgeon.

Authors:  M Adamina; U Guller; W P Weber; D Oertli
Journal:  Br J Surg       Date:  2006-04       Impact factor: 6.939

3.  Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.

Authors:  Xiaobin Feng; Ruocai Xu; Xilin Du; Kefeng Dou; Xiao Qin; Jun Xu; Weidong Jia; Zhiming Wang; Hongzhi Zhao; Shufa Yang; Chenyang Guo; Tianqi Liu; Kuansheng Ma
Journal:  Am J Gastroenterol       Date:  2014-11-18       Impact factor: 10.864

4.  Introduction to propensity scores: A case study on the comparative effectiveness of laparoscopic vs open appendectomy.

Authors:  Mark R Hemmila; Nancy J Birkmeyer; Saman Arbabi; Nicholas H Osborne; Wendy L Wahl; Justin B Dimick
Journal:  Arch Surg       Date:  2010-10

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115
  5 in total
  1 in total

1.  Response to Yang et al.

Authors:  Xiaobin Feng; Kuansheng Ma
Journal:  Am J Gastroenterol       Date:  2015-04       Impact factor: 10.864
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.